Some psychiatric medications, including stimulants for ADHD and benzodiazepines for anxiety, are controlled substances regulated by the DEA because they carry risk of misuse and dependence. That status brings extra rules: a DEA registration to prescribe, tighter refill and documentation requirements, prescription drug monitoring program checks, and special considerations for prescribing by telemedicine. Those rules reshape how a practice runs, not just what gets prescribed.
Key takeaways
- Controlled substances are scheduled by the DEA based on accepted use and risk of misuse.
- Prescribing them requires a DEA registration and triggers extra documentation and monitoring.
- Schedule II drugs like many stimulants have stricter refill rules than ordinary prescriptions.
- Telemedicine prescribing of controlled substances is governed by federal flexibilities currently extended through 2026.
Why some drugs are controlled
A number of effective psychiatric medications also carry a risk of misuse, dependence, or diversion. Stimulants used for ADHD and benzodiazepines used for anxiety and panic are the clearest examples. Because of that risk, the federal government, through the Drug Enforcement Administration, classifies them as controlled substances and regulates how they're prescribed, stored, and tracked. This isn't a judgment that the medications are bad. Many are genuinely helpful. It's a recognition that they need guardrails ordinary medications don't.
What the schedules mean
Controlled substances are sorted into schedules from II to V, based roughly on accepted medical use and potential for misuse. Schedule II includes drugs with high misuse potential that still have clear medical uses, and it covers many common stimulants. Schedules III through V carry progressively lower misuse potential and looser rules. The schedule a drug sits in determines a lot: how it can be refilled, how prescriptions are transmitted, and how closely the prescriber has to track it.
The rules that follow
To prescribe any controlled substance, a clinician needs a DEA registration, which is separate from a medical license. Schedule II medications, including many stimulants, generally can't be refilled the way an ordinary prescription can; a new prescription is required each time, which is why patients on stimulants often have to check in more regularly. Documentation expectations are higher, because the prescriber needs to show a legitimate medical purpose and ongoing monitoring. Even the logistics of how a prescription is sent are more tightly regulated.
Monitoring and the PDMP
Most states run a prescription drug monitoring program, usually shortened to PDMP, a database that records controlled-substance prescriptions. Prescribers are often required, or strongly expected, to check it before prescribing, so they can see whether a patient is receiving similar medications elsewhere. This is a safety tool and a compliance step at once, and it's part of the routine of prescribing controlled substances that patients rarely see.
Telemedicine and the moving target
Prescribing controlled substances over telemedicine is its own evolving area. During the COVID-19 public health emergency, federal rules were relaxed so clinicians could prescribe controlled medications by video without a prior in-person visit. Those flexibilities have been extended several times. As of the most recent extension, the DEA and the Department of Health and Human Services continued them through the end of 2026 while the agencies work on permanent rules, including a proposed special registration for telemedicine prescribing. For a practice, that means the rules in this corner can change, and staying current is part of the job. We cover the broader picture in what telepsychiatry changes.
How it reshapes the practice
All of this changes day-to-day operations. Patients on Schedule II medications generally need more frequent visits, which fills the schedule differently. The practice has to track DEA registration, follow PDMP requirements, and keep tighter records. Some psychiatrists limit how much controlled-substance prescribing they do, not because the medications don't work, but because the regulatory weight is real. The rules are a feature of the whole practice, not just a footnote on a prescription.
What's commonly misunderstood
Patients sometimes feel that frequent check-ins for a stimulant or a refusal to call in a benzodiazepine refill means the psychiatrist doesn't trust them. Usually it reflects rules the prescriber is legally bound to follow, plus a genuine duty to monitor medications that carry real risks. The flip side is the assumption that controlled means dangerous or addictive for everyone; for many patients these medications are safe and effective when monitored. The point of the rules is to make that careful monitoring the default.
Common questions
Why can't a psychiatrist just refill my stimulant like other medications?
Many stimulants are Schedule II controlled substances, which generally can't be refilled the way ordinary prescriptions can. A new prescription is required each time, and prescribers are expected to monitor regularly, so more frequent check-ins are common.
What is a PDMP?
A prescription drug monitoring program is a state database of controlled-substance prescriptions. Prescribers often check it before prescribing to see a patient's controlled-substance history and reduce the risk of harmful combinations or diversion.
Can controlled substances be prescribed over telehealth?
Currently, yes, under federal flexibilities that have been extended through the end of 2026 while permanent rules are finalized. This area is evolving, so the specifics can change.
Sources
- DEA, drug scheduling overview. https://www.dea.gov/drug-information/drug-scheduling
- DEA, extension of telemedicine flexibilities for controlled-substance prescribing (Dec 2025). https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care
- HHS, DEA telemedicine extension through 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html